Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6241636 | Respiratory Medicine | 2015 | 7 Pages |
Abstract
The prevalence of lung cancer in lung transplant recipients is low. Using accepted donor screening criteria, donor derived malignancy is exceptionally rare. While stage I disease is associated with improved survival in this cohort, survival is still not comparable to that of the general population, likely influenced by the need for aggressive immune suppression.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Amardeep S. Grewal, Robert F. Padera, Steve Boukedes, Miguel Divo, Ivan O. Rosas, Phillip C. Camp, Anne Fuhlbrigge, Hilary Goldberg, Souheil El-Chemaly,